ITRI vs SAIC
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ITRI exhibits strong fundamental health with a Piotroski F-Score of 7/9 and a highly attractive valuation profile, trading significantly below its growth-based intrinsic value of $191.75. While the technical trend is bearish and insider sentiment is low, the company's profitability is robust with an ROE of 19.26% and a PEG ratio of 0.82, indicating the stock is undervalued relative to its earnings growth. The primary concern is a recent decline in revenue growth (-6.70%), though this is heavily offset by massive earnings growth (73.60%) and a consistent track record of earnings beats. Overall, the data suggests a value-driven entry point for a company with strong operational efficiency.
SAIC presents a conflicted profile with a Piotroski F-Score of 4/9, indicating stable but non-improving financial health. The stock is currently trading at a significant premium to both its Graham Number ($76.85) and Intrinsic Value ($53.90), suggesting it is overvalued based on deterministic models. While the company maintains a strong ROE of 23.27% and a consistent track record of beating earnings estimates, this is offset by negative YoY revenue (-4.80%) and earnings growth (-6.20%). The bearish technical trend and high debt-to-equity ratio further temper the outlook.
Compare Another Pair
Related Comparisons
ITRI vs SAIC: Head-to-Head Comparison
This page compares Itron, Inc. (ITRI) and Science Applications International Corporation (SAIC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.